Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling

Phytomedicine. 2022 Dec:107:154444. doi: 10.1016/j.phymed.2022.154444. Epub 2022 Sep 6.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is a major clinical and public health burden worldwide with no established pharmacological therapy. Changes in the intestinal flora and associated metabolite bile acids (BAs) have been described in NAFLD. Astragaloside IV (AS-IV) is a low drug permeability saponin with protective effects against multiple diseases. However, the specific mechanism underlying the involvement of AS-IV in the regulation of NAFLD is yet to be clarified.

Purpose: This study aimed to investigate the effect of AS-IV on NAFLD and explore whether intestinal flora was involved.

Methods: The effect of AS-IV was evaluated on high-fat diet-fed mice. Real-time PCR, immunohistochemistry, immunofluorescence, and biochemical analyses were performed. 16S rRNA gene sequencing and UPLC-TQMS were used to determine the alterations in the intestinal flora and concentration of BAs. Fecal microbiota transplantation (FMT) and intestine-specific farnesoid X receptor (FXR) knockout were also performed.

Results: AS-IV treatment alleviated diet-induced metabolic impairments, particularly hepatic steatosis. These changes occurred in the setting of decreased intestinal bile salt hydrolase (BSH)-expressing flora. Further analysis showed that the reduced BSH activity increased intestinal tauro-β-muricholic acid levels, an inhibitor of intestinal FXR. Inhibition of intestinal FXR signaling by AS-IV was accompanied by decreased expression of intestinal fibroblast growth factor 15 and subsequent hepatic FXR activation as well as increased glucagon-like peptide-1 and decreased ceramide production, all of which contribute to the inhibition of sterol regulatory element-binding protein-1c-mediated hepatic steatosis. Furthermore, intestine-specific Fxr knockout and FMT further demonstrated an FXR- and intestinal flora-dependent preventive effect of AS-IV on hepatic steatosis.

Conclusion: These results show that the changes in intestinal flora and BAs serve an essential role in the remission of hepatic steatosis by AS-IV, thereby suggesting that AS-IV may be used as a prebiotic agent to provide viable treatment for NAFLD.

Keywords: Astragaloside IV; Bile acid; Farnesoid X receptor; Hepatic steatosis; Intestinal flora.

MeSH terms

  • Animals
  • Bile Acids and Salts / metabolism
  • Ceramides / metabolism
  • Ceramides / pharmacology
  • Diet, High-Fat / adverse effects
  • Fibroblast Growth Factors / metabolism
  • Gastrointestinal Microbiome*
  • Glucagon-Like Peptide 1 / metabolism
  • Intestines
  • Liver
  • Mice
  • Mice, Inbred C57BL
  • Mice, Obese
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Non-alcoholic Fatty Liver Disease* / metabolism
  • RNA, Ribosomal, 16S
  • Receptors, Cytoplasmic and Nuclear / metabolism
  • Saponins* / metabolism
  • Saponins* / pharmacology
  • Sterols / metabolism
  • Triterpenes

Substances

  • Bile Acids and Salts
  • Ceramides
  • RNA, Ribosomal, 16S
  • Receptors, Cytoplasmic and Nuclear
  • Saponins
  • Sterols
  • Triterpenes
  • astragaloside A
  • Fibroblast Growth Factors
  • Glucagon-Like Peptide 1